{"title":"How to treat advanced Hodgkin lymphoma?","authors":"Cédric Rossi, René-Olivier Casasnovas","doi":"10.1097/CCO.0000000000001070","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we analyzed the different therapy options in patients with advanced Hodgkin lymphoma (HL).</p><p><strong>Recent findings: </strong>The treatment of advanced HL has greatly evolved during the last decade even still based on polychemotherapy. Mature data established that the better strategies require Positron emission tomography (PET)-driven treatments which allow to optimize the balance between disease control and both immediate and late treatment adverse effects, leading to cure most patients while minimizing the risk of toxicity. Indeed, PET-driven deescalated strategies offer the better treatment option. The recent incorporation of targeted therapies, anti-CD30 or anti-programmed cell death protein 1 (PD1) in combination with chemotherapy should quickly change the game and be a step forward to still decrease the risk of treatment toxicity and improve the cure rate.</p><p><strong>Summary: </strong>The standard of care for advanced HL remains currently PET-driven chemotherapy and should rapidly evolve with the addition of targeted therapy combined with chemotherapy.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"339-345"},"PeriodicalIF":2.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001070","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: In this review, we analyzed the different therapy options in patients with advanced Hodgkin lymphoma (HL).
Recent findings: The treatment of advanced HL has greatly evolved during the last decade even still based on polychemotherapy. Mature data established that the better strategies require Positron emission tomography (PET)-driven treatments which allow to optimize the balance between disease control and both immediate and late treatment adverse effects, leading to cure most patients while minimizing the risk of toxicity. Indeed, PET-driven deescalated strategies offer the better treatment option. The recent incorporation of targeted therapies, anti-CD30 or anti-programmed cell death protein 1 (PD1) in combination with chemotherapy should quickly change the game and be a step forward to still decrease the risk of treatment toxicity and improve the cure rate.
Summary: The standard of care for advanced HL remains currently PET-driven chemotherapy and should rapidly evolve with the addition of targeted therapy combined with chemotherapy.
综述的目的：在这篇综述中，我们分析了晚期霍奇金淋巴瘤（HL）患者的不同治疗方案：最近的研究结果：晚期霍奇金淋巴瘤的治疗方法在过去十年间有了很大的发展，但仍以多化疗为主。成熟的数据表明，更好的治疗策略需要正电子发射断层扫描（PET）驱动的治疗，这种治疗可以优化疾病控制与近期和后期治疗不良反应之间的平衡，从而治愈大多数患者，同时将毒性风险降至最低。事实上，正电子发射计算机断层显像（PET）驱动的降级策略提供了更好的治疗选择。小结：目前，晚期 HL 的治疗标准仍然是 PET 驱动的化疗，随着靶向治疗与化疗的结合，这一标准将得到迅速发展。
期刊介绍：
With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
